Fine Foods & Pharmaceuticals N.T.M. SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0005215329
EUR
8.22
0.02 (0.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 3.14%

  • Poor long term growth as Operating profit has grown by an annual rate 187.54% of over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 6.17 times
2

Flat results in Dec 21

3

With ROE of 9.07%, it has a Expensive valuation with a 1.47 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 234 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.09

stock-summary
Return on Equity

9.09%

stock-summary
Price to Book

1.70

Revenue and Profits:
Net Sales:
62 Million
(Quarterly Results - Dec 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.29%
0%
-13.29%
6 Months
-5.52%
0%
-5.52%
1 Year
14.48%
0%
14.48%
2 Years
-1.44%
0%
-1.44%
3 Years
-0.96%
0%
-0.96%
4 Years
-36.77%
0%
-36.77%
5 Years
-24.93%
0%
-24.93%

Fine Foods & Pharmaceuticals N.T.M. SpA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
3.39%
EBIT Growth (5y)
187.54%
EBIT to Interest (avg)
1.77
Debt to EBITDA (avg)
2.21
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
0.76
Tax Ratio
29.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.14%
ROE (avg)
2.06%

Valuation key factors

Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.47
EV to EBIT
13.42
EV to EBITDA
7.29
EV to Capital Employed
1.35
EV to Sales
1.01
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
10.02%
ROE (Latest)
9.07%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -6.32% vs 0.61% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -160.00% vs 183.33% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.30",
          "val2": "66.50",
          "chgp": "-6.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.30",
          "val2": "7.30",
          "chgp": "-13.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "1.50",
          "chgp": "-160.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.60%",
          "val2": "49.20%",
          "chgp": "-4.56%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 3.40% vs -3.18% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23.17% vs 334.29% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "252.10",
          "val2": "243.80",
          "chgp": "3.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.30",
          "val2": "29.40",
          "chgp": "13.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "3.40",
          "chgp": "-11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "-0.10",
          "chgp": "400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.10",
          "val2": "8.20",
          "chgp": "23.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.70%",
          "val2": "56.00%",
          "chgp": "0.47%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
62.30
66.50
-6.32%
Operating Profit (PBDIT) excl Other Income
6.30
7.30
-13.70%
Interest
0.80
0.80
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.90
1.50
-160.00%
Operating Profit Margin (Excl OI)
3.60%
49.20%
-4.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -6.32% vs 0.61% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -160.00% vs 183.33% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
252.10
243.80
3.40%
Operating Profit (PBDIT) excl Other Income
33.30
29.40
13.27%
Interest
3.00
3.40
-11.76%
Exceptional Items
0.30
-0.10
400.00%
Consolidate Net Profit
10.10
8.20
23.17%
Operating Profit Margin (Excl OI)
60.70%
56.00%
0.47%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 3.40% vs -3.18% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 23.17% vs 334.29% in Dec 2024

stock-summaryCompany CV
About Fine Foods & Pharmaceuticals N.T.M. SpA stock-summary
stock-summary
Fine Foods & Pharmaceuticals N.T.M. SpA
Pharmaceuticals & Biotechnology
Fine Foods & Pharmaceuticals NTM SpA, formerly Innova Italy 1 SpA, is an Italy-based pharmaceutical company. It is specialized in the manufacturing of pharmaceutical products for third parties. The Company manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.
Company Coordinates stock-summary
Company Details
Via Berlino, 39, Zingonia , VERDELLINO None : 24040
Registrar Details